JPMorgan analyst Anupam Rama lowered the firm’s price target on Rapt Therapeutics to $13 from $15 and keeps a Neutral rating on the shares. The analyst updated the company’s model to include expenses and share count.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RAPT:
- RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
- Rapt Therapeutics reports Q4 EPS (80c), consensus (86c)
- RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting
- Rapt Therapeutics Inc (RAPT) Q4 Earnings Cheat Sheet
- Biotech Alert: Searches spiking for these stocks today